Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Frederick Haynes Van der Merwe has a total of 28 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Comparison of self‐sampling versus clinician‐sampling HPV DNA cervical cancer screening in South African women living with and without HIV

    by Leon C. Snyman, Cathy Visser, Gerrit J. Dreyer, Azwidowi Lukhwareni, F. Haynes van der Merwe, Matthys H. Botha, Karin Richter, Greta Dreyer

    Introduction: Human papilloma virus (HPV) testing is the preferred primary screening method for cervical cancer, and HPV self‐sampling has the potential to improve screening uptake. We compared the test performance and agreement of self‐ and clinician‐sampling HPV in women living with HIV (WLWH) and HIV‐negative women in Gauteng and Western Cape Province, South Africa. Methods: Cervical cancer screening was performed in previously unscreened women using cytology, self‐ and clinician‐collected HPV (Hybrid Capture 2 assay). Screen‐positive participants underwent colposcopy and biopsy, and a random sample of negative screens had punch biopsy regardless of colposcopy findings. Performances of screening tests were evaluated against histology results adjusted for verification bias. The kappa statistic for HPV concordance between self‐ and clinician‐collected HPV was also calculated. Results: Included for analysis were 903 women with a mean age of 41.5 years, of which 43.3% were WLWH. In WLWH/HIV‐negative women, the sensitivity of self‐sampling HPV was 74.7%/67.4% and of clinician‐sampling HPV was 77.1%/59.2% to detect cervical intraepithelial neoplasia (CIN) grade3+, whereas the specificity for clinician‐sampling HPV was 75.0%/86.8% compared with 70.3%/79.8% for self‐sampling HPV to detect CIN2+. In both HIV groups, Cohen's kappa agreement between the two sampling methods was good (0.63 and 0.62, respectively). Conclusion: Self‐collected HPV sampling is an acceptable and viable option for primary cervical cancer screening in all women given the superior sensitivity to cytology. The statistically significant difference in HPV test performance among HIV‐negative women according to sampling method confirms the benefit of a further triage test when self‐sampling is used for HPV‐base cervical screening, especially in HIV‐negative women.

  • Open Access

    Extended Genotyping as Triage of HPV Positive Screened Women in Low‐and‐Middle Income Countries

    by Frederick H. van der Merwe, Greta Dreyer, Cathy Visser, Gerrit J. Dreyer, Karin Richter, Leon C. Snyman, Robyn Adams, Matthys H. Botha

    Cervical cancer screening coverage in low‐ and middle‐income countries is low, and many screened women are lost to follow‐up. Point‐of‐care testing that allows same‐day treatment could reduce the incidence of this cancer, but same‐day triage testing is required to prevent overtreatment and minimise loss‐to‐follow‐up before treatment. Built‐in extended genotyping with the Xpert® human papilloma virus (HPV) assay offers point‐of‐care triage, but treatment thresholds differ. We calculated test performance of the Xpert® HPV assay for HIV‐positive and HIV‐negative women. Extended HPV‐genotyping was evaluated against histology and missing values were imputed to correct for verification bias. We report test performance at different thresholds, namely Top3 (HPV16, 18, 45), Top8 (HPV16, 18, 45, 31, 33, 35, 52, 58) and Top14 (HPV16, 18, 45, 31, 33, 35, 52, 58, 51, 59, 39, 56, 66, 68) hierarchical viral types. Included were 1063 participants, aged 25–65 years, mean age 41.2 years; 42.7% were HIV‐positive. HIV‐positive women were significantly more likely to test positive on multiple test channels and were more likely to have histology proven disease. Screening only for Top3, sensitivity (CIN3+) was 31.3%/41.5%, and specificity (CIN2+) 97.0%/95.6% for HIV‐negative/HIV‐positive women respectively. Top8 rendered results of 57.8%/76.4% and 91.8%/84.6% respectively, which is acceptable for a triage test. Treatment at the threshold of Top8 types requires less than three referrals among all HIV‐groups for one case of histology proven disease. Results confirmed screening for all 14 high‐risk HPV types is most sensitive but necessitates triage. Extended genotyping using a threshold of Top8 oncogenic types rendered best balance of sensitivity and specificity and overall test performance for both HIV‐groups in a test‐and‐treat strategy. Clinical Trial Registration: The study was registered as Trial ID NCT02956031 on ClinicalTrials. gov.


  • Open Access

    Profile of surgical complications in gynaecology at a teaching hospital in South Africa

    by T Gallant, Haynes Van der Merwe

    Background. Information about current gynaecological surgical practices and patient outcomes is integral to the provision of quality gynaecological care. An audit of surgical complications can provide important information needed for an assessment of current surgical practices and outcomes. Objective. To describe the cohort of patients undergoing gynaecological surgical procedures at Tygerberg Hospital, their complication rates and identify associated risk factors. Methods. We conducted a retrospective review of adult patients having emergency and elective gynaecological surgical procedures between 1 January and 31 December 2019. A total of 970 patients were included. We summarised categorical data as counts and percentages. We performed logistical regressions to assess factors associated with complications. Odds ratios (ORs) were reported as measures of association with the corresponding 95% confidence interval (CI). Statistical significance was set at a p-value <0.1 and p-value <0.05 in the bivariate and multivariate analysis, respectively. Results. Overweight and obese patients accounted for 60% of patients. The most common indication for surgical intervention was benign gynaecological conditions (23.3%). Total abdominal hysterectomy was the single most common procedure performed (23.7%). Intraoperative or postoperative complications occurred in 12.7% of patients, while 1.2% sustained both intraoperative and postoperative complications. The most common complications were infection-related (7.5%) and bowel injury (1.8%). Oncological surgery did not increase the likelihood of complications compared with non-oncological surgery (OR 1.14; 95% CI 0.66 - 1.97; p=0.63). Conclusion. The provision of quality gynaecological care requires information on gynaecological surgical practices and patient outcomes. The rates of surgical complications at our facility appear to be higher than local and international studies, with our main contributors being infection-related complications and bowel injuries. An extended course of prophylactic antibiotics could be considered, as well as auditing infection control measures. Patients who are at a higher risk of bowel injury should be identified preoperatively and the surgery approached with care.

  • Aptima HPV E6/E7 mRNA and cytology cross-sectional performance as primary screening tests for detection of high-grade cervical lesions in HIV positive and negative women in South Africa

    by Karin Louise Richter, Leon Cornelius Snyman, Greta Dreyer, Frederick Haynes Van der Merwe, Gerrit Jan Dreyer, Cathy Visser, Matthys Hendrik Botha

    Objective: To assess the performance of APTIMA ® HPV E6/E7 mRNA assay (AHPV) with HPV 16 and 18/45 genotyping (AHPV-GT) and cytology in detecting cervical cancer and precancer in HIV positive and negative women in South Africa. Methods: A multicentre cross-sectional study was performed in women aged 25–64 (n = 992) with cytology and AHPV with AHPV-GT reflex testing. All screen-positive and a random subset of screen-negative women were referred for colposcopy and biopsy. Results: On cytology, low-grade squamous intraepithelial lesion (LSIL) or higher was found in 9.7% of HIV negative and 35.8% of HIV positive women. HPV mRNA positivity was 19.5% (4.4% HPV 16, 2.8% HPV 18/45, and 6.9% other high-risk HPV) in HIV negative women, compared to 45.8% (9.4% HPV 16, 9.7% HPV 18/45, and 27.6% other high-risk HPV) in HIV positive women . The prevalence of histological abnormalities in HIV negative vs HIV positive women was 24.3 vs 46.0% for cervical intraepithelial neoplasia (CIN) 2+, 10.2 vs 24.1% for CIN3+, and 1.4 vs 2.4% for invasive squamous cell carcinoma. AHPV sensitivity for detection of CIN3 + performed the best: 69.0% (95% confidence interval (CI) 56.8–81.1) in HIV negative vs 81.4% (95% CI 73.7–89.0) in HIV positive women, followed by ASCUS + (atypical squamous cells of undetermined significance) cytology: 58.6% (95% CI 45.7–71.6) vs 76.5% (95% CI 68.1–84.8). The best positive predictive value for CIN2 + was for AHPV-GT16, followed by AHPV-GT16,18/45 and cytology LSIL+: HIV-negative women 84.0% (95% CI 68.9–99.1); 76.9% (95% CI 63.3–90.6); 75.0% (95 CI% 61.2–88.9) and HIV-positive women 92.5% (95% CI 84.1–100); 86.8% (95% CI 79.1–94.6); 84.0% (95% CI 77.6–90.3). Conclusion: Significantly more HPV infection and cytological/histological abnormalities and advanced disease were seen in HIV positive women. The lower than expected clinical sensitivities of all screening tests are comparable to HPV DNA sensitivities reported in similar populations. AHPV with AHPV-GT performed better than cytology as a screening and triage test.


  • Targeting treatment resistance in cervical cancer: A new avenue for senolytic therapies

    by Madré Meyer, Carla Fourie, Haynes van der Merwe, Hennie Botha, Anna-Mart Engelbrecht


  • Open Access

    Sociodemographics, behaviour and knowledge of first South African HPV-vaccine recipients

    by Robyn A. Adams, Cathy Visser, Greta Dreyer, Leon Snyman, Frederick H. van der Merwe, Matthys H. Botha

    Background: Infection with the human papillomavirus (HPV) is a necessary cause of cervical cancer and is one of the most prevalent sexually transmitted infections worldwide. Primary prevention strategies target reducing HPV acquisition through vaccination, limiting exposure (e.g. delayed sexual debut, barrier contraception) and health education focusing on sexual behaviour and tobacco use. Methods: The ImmunoVACCS study, conducted from 2019 to 2022 in two provinces in South Africa, examined sociodemographic characteristics, sexual practices, and knowledge of cervical cancer and the HPV vaccine among young female vaccine recipients. It encompassed participants from the previously conducted vaccine implementation trials, VACCS 1 and VACCS 2 (2011–2014). Recruitment involved telephonic contact with eligible potential participants. Data were collected through self-administered questionnaires. Results: One hundred and eleven participants took part in the current study (median age: 20 years; age range: 16–22 years). Most sexually active participants had their first engagement in secondary school (96.2%), and 77.2% used contraception during their last sexual activity. Knowledge gaps were evident, with only 13.5% recognising cervical cancer’s cervix origin and 3.6% attributing it to a virus. Despite this, 70.3% had heard of a vaccine for cervical cancer. Less than half knew about the importance of regular Pap smears (49.5%), vaccine protection (44.1%) or condom use (20.7%) against HPV and cervical cancer. Conclusion: The current study demonstrates that young women still lack complete information on cervical cancer and its risk factors even after receiving health education linked with vaccination. Contribution: This study underscores the necessity of ongoing education about HPV, its risks and preventive measures among young women to combat cervical cancer.


  • Open Access

    Enhancing Cervical Cancer Prevention in South African Women: Primary HPV mRNA Screening with Different Genotype Combinations

    by Sveinung Wergeland Sørbye, Bente Marie Falang, Matthys H. Botha, Leon Cornelius Snyman, Haynes van der Merwe, Cathy Visser, Karin Richter, Greta Dreyer

    Background: Cervical cancer prevention in regions with limited access to screening and HPV vaccination necessitates innovative approaches. This study explored the potential of a test-and-treat strategy using mRNA HPV tests to impact cervical cancer prevention in a high-prevalence HIV population. Methods: A cervical screening study was conducted at three South African hospitals involving 710 under-screened, non-pregnant women (25 to 65 years) without known cervical diseases. Cytology, HPV testing, colposcopy, and biopsies were performed concurrently. Histopathologists determined final histological diagnoses based on biopsy and LLETZ histology. mRNA-HPV-genotyping for 3 (16, 18, 45) to 8 (16, 18, 31, 33, 35, 45, 52, 58) high-risk types was performed on leftover liquid-based cytology material. The preventive potential of the test-and-treat approach was estimated based on published data, reporting the causative HPV types in cervical cancer tissue from South African women. Treatment was provided as needed. Results: The HPV positivity rate more than doubled from 3-type (15.2%; 95% CI: 12.6–17.8) to 8-type mRNA (31.5%; 95% CI: 28.8–34.9) combinations, significantly higher among HIV-positive women. CIN3+ prevalence among HIV-positive women (26.4%) was double that of HIV-negative women (12.9%) (p < 0.01). The 6-type combination showed the best balance of sensitivity, specificity and treatment group size, and effectiveness to prevent cervical cancer. A 4-type combination (16, 18, 35, 45) could potentially prevent 77.6% (95% CI: 71.2–84.0) of cervical cancer burden by treating 20% and detecting 41.1% of CIN3 cases in the study group. Similarly, a 6-type combination (16, 18, 31, 33, 35, 45), treating 25% and including 62% of CIN3 cases, might prevent 85% of cervical cancer cases (95% CI: 79.6–90.6) among HIV-positive and negative women. Conclusion: Employing mRNA HPV tests within a test-and-treat approach holds huge promise for targeted cervical cancer prevention in under-screened populations. Testing for mRNA of the 6 highest-risk HPV types in this population and treating them all is projected to effectively prevent progression from CIN3 to invasive cervical cancer while reducing overtreatment in resource-constrained settings.


  • Open Access

    Enhancing Cervical Cancer Prevention in South African Women: Primary HPV mRNA Screening with Different Genotype Combinations

    by Sveinung Wergeland Sørbye, Bente Marie Falang, Hennie Botha, Leon Snyman, Haynes Van Der Merwe, Cathy Visser, Karin Richter, Greta Dreyer

    Background: Cervical cancer prevention in regions with limited access to screening and HPV vaccination necessitates innovative approaches. This study explored the potential of a test-and-treat strategy using mRNA HPV tests to impact cervical cancer prevention in a high-prevalence HIV population. Methods: A cervical screening study was conducted at three South African hospitals involving 710 under-screened, non-pregnant women (25 to 65 years) without known cervical diseases. Cytology, HPV testing, colposcopy, and biopsies were performed concurrently. Histopathologists determined final histological diagnoses based on biopsy and LLETZ histology. mRNA-HPV-genotyping for 3 (16, 18, 45) to 8 (16, 18, 31, 33, 35, 45, 52, 58) high-risk types was performed on leftover liquid-based cytology material. The preventive potential of the test-and-treat approach was estimated based on published data, reporting the causative HPV types in cervical cancer tissue from South African women. Treatment was provided as needed. Results: HPV positivity rate more than doubled from 3-type (15.2%; 95% CI: 12.6-17.8) to 8-type mRNA (31.5%; 95% CI: 28.8-34.9) combinations, significantly higher among HIV-positive women. CIN3+ prevalence among HIV-positive women (26.4%) was double that of HIV-negative women (12.9%) (p<0.01). The 6-type combination showed the best balance of sensitivity, specificity and treatment group size, and effectiveness to prevent cervical cancer. A 4-type combination (16, 18, 35, 45) could potentially prevent 77.6% (95% CI: 71.2-84.0) of cervical cancer burden by treating 20% and detecting 41.1% of CIN3 cases in the study group. Similarly, a 6-type combination (16, 18, 31, 33, 35, 45), treating 25% and including 62% of CIN3 cases, might prevent 85% of cervical cancer cases (95% CI: 79.6-90.6) among HIV-positive and negative women. Conclusion: Employing mRNA HPV tests within a test-and-treat approach holds huge promise for targeted cervical cancer prevention in under-screened populations. Testing for mRNA of the 6 highest-risk HPV types in this population and treating them all is projected to effectively prevent progression from CIN3 to invasive cervical cancer while reducing overtreatment in resource-constrained settings.


  • Open Access

    Exploring the feasibility of using mobile phones to improve the management of clients with cervical cancer precursor lesions

    by Jennifer Moodley, Deborah Constant, Matthys H. Botha, Frederick H. van der Merwe, Amanda Edwards, Mariette Momberg

    Cancer screening programs hold much potential for reducing the cervical cancer disease burden in developing countries. The aim of this study was to determine the feasibility of mobile health (mHealth) phone technology to improve management and follow-up of clients with cervical cancer precursor lesions. A sequential mixed methods design was employed for this study. Quantitative data was collected using a cross-sectional survey of 364 women eligible for a Pap smear at public sector health services in Cape Town, South Africa. Information was collected on socio-demographic status; cell phone ownership and patterns of use; knowledge of cervical cancer prevention; and interest in Pap smear results and appointment reminders via SMS-text messages. Descriptive statistics, crude bivariate comparisons and logistic regression models were employed to analyze survey results. Qualitative data was collected through 10 in-depth interviews with primary health care providers and managers involved in cervical cancer screening. Four focus group discussions with 27 women attending a tertiary level colposcopy clinic were also conducted. Themes related to loss of mobile phones, privacy and confidentiality, interest in receiving SMS-text messages, text language and clinic-based management of a SMS system are discussed. Thematic analyses of qualitative data complemented quantitative findings. Phone ownership amongst surveyed women was 98% with phones mostly used for calls and short message service (SMS) functions. Over half (58%) of women reported loss/theft of mobile phones. Overall, there was interest in SMS interventions for receiving Pap smear results and appointment reminders. Reasons for interest, articulated by both providers and clients, included convenience, cost and time-saving benefits and benefits of not taking time off work. However, concerns were expressed around confidentiality of SMS messages, loss/theft of mobile phones, receiving negative results via SMS and accessibility/clarity of language used to convey messages. Responsibility for the management of a clinic-based SMS system was also raised. Results indicated interest and potential for mHealth interventions in improving follow-up and management of clients with abnormal Pap smears. Health system and privacy issues will need to be addressed for mHealth to achieve this potential. Next steps include piloting of specific SMS messages to test feasibility and acceptability in this setting.